Oppenheimer Maintains a Buy Rating on Viewray (VRAY)

In a report released yesterday, Suraj Kalia from Oppenheimer maintained a Buy rating on Viewray (VRAYResearch Report), with a price target of $6.00. The company’s shares closed last Thursday at $4.15.

According to TipRanks.com, Kalia is a 4-star analyst with an average return of 9.7% and a 55.9% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Inspire Medical Systems, and Cardiovascular Systems.

Viewray has an analyst consensus of Strong Buy, with a price target consensus of $6.33.

See today’s analyst top recommended stocks >>

The company has a one-year high of $7.36 and a one-year low of $1.11. Currently, Viewray has an average volume of 2.21M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ViewRay, Inc. engages in the design, manufacture and market magnetic resonance imaging (MRI) system. It develops MRIdian to address the key limitations of existing external-beam radiation therapy technologies, and employs MRI-based technology to provide real-time imaging that clearly defines the targeted tumor from the surrounding soft tissue, and other critical organs, both before and during radiation treatment delivery. The company was founded by Dinara Akzhigitova on September 6, 2013 and is headquartered in Oakwood Village, OH.